PTC Therapeutics (PTCT) Tops Q1 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to PTC Therapeutics (PTCT) Tops Q1 EPS by 18c

PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 8, 2017 7:30 AM EDT

SOUTH PLAINFIELD, N.J., May 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2017.

"We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients in the United States," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "The acquisition of EMFLAZA supports our commitment to providing new treatment options for Duchenne patients. We plan to launch EMFLAZA in the coming weeks and are focused on providing access to all eligible patients. We... More